PDCD1 and cancer: Anti-programmed cell death protein 1 (PD-1) antibodies such as nivolumab and pembrolizumab are in wide use for the treatment of various cancers, including advanced melanoma (1, 2), but cost-effective analyses of their use are sometimes controversial (3).